Results 161 to 170 of about 272,745 (291)

USP5 Stabilizes TGFBR1 to Drive Vascular Smooth Muscle Cell Senescence and Atherosclerosis

open access: yesAdvanced Science, EarlyView.
This study reveals that USP5 drives vascular smooth muscle cell senescence and atherosclerosis by stabilizing TGFBR1, suppressing IDH2, and promoting glycolytic reprogramming, identifying the USP5‐TGFBR1‐IDH2 axis as a potential therapeutic target. ABSTRACT Vascular smooth muscle cell (VSMC) senescence contributes importantly to atherosclerotic plaque ...
Xinhai Cui   +5 more
wiley   +1 more source

Fibrillarin Resists Cellular Senescence Via SIRT1‐Dependent Nicotinamide Metabolism and Its Inhibition Sensitizes Senolytic Therapy in Esophageal Squamous Cell Carcinoma

open access: yesAdvanced Science, EarlyView.
FBL directly binds to and stabilizes SIRT1 by blocking its ubiquitin‐proteasome degradation, thereby sustaining nicotinamide metabolism and redox homeostasis to counteract cellular senescence in ESCC. Genetic and pharmacological suppression of FBL sensitizes tumor cells to senolytic therapy.
Xing Jin   +9 more
wiley   +1 more source

Small Molecule Stabilization of Diverse Amyloidogenic Immunoglobulin Light Chains Revealed by Hydrogen-Deuterium Exchange Mass Spectrometry. [PDF]

open access: yesJ Mol Biol
Peterle D   +11 more
europepmc   +1 more source

Engineered Xenogeneic Bone Scaffold with IL‐10 Nanodelivery System: Immunomodulation and BMSC Fate Programming for Skull Defect Repair

open access: yesAdvanced Science, EarlyView.
A multifunctional regenerative composite is constructed by 3D‐printing thermosensitive PNIPAM hydrogel embedded with MPDA@IL‐10 nanoparticles and autologous BMSCs onto antigen‐depleted porcine bone matrix for beagle critical‐sized skull defect reconstruction.
Weihao Lv   +16 more
wiley   +1 more source

PARP Inhibitors plus Anlotinib as Bridging Therapy for Armored CAR‐T Cells in Ovarian Cancer Enhances Infiltration and Antitumor Efficacy

open access: yesAdvanced Science, EarlyView.
This study shows that a PARP inhibitor combined with anlotinib, administered as bridging therapy, preconditions the tumor microenvironment to enhance the infiltration and antitumor activity of subsequently infused CAR‐T cells across preclinical ovarian cancer models, supporting bridging therapy as a promising strategy to address limited CAR‐T cell ...
Huayi Li   +20 more
wiley   +1 more source

Home - About - Disclaimer - Privacy